RATIONALE: Gathering information about how often metabolic syndrome occurs in young survivors of childhood leukemia who have undergone stem cell transplant may help doctors learn more about the disease and the long-term effects of leukemia treatment. It may also help improve the quality of life for future cancer survivors. PURPOSE: This clinical trial is studying metabolic syndrome in adolescent and young adult survivors of childhood leukemia who have undergone stem cell transplant.
Age range
9 Years – 21 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Comparison of the prevalence of metabolic syndrome in adolescent and young adult survivors of childhood leukemia who have undergone hematopoietic stem cell transplantation (HSCT) with age- and gender-matched controls
Timeframe: ≥2 years post-HSCT
Comparison of insulin resistance in patients with age- and gender-matched controls
Timeframe: ≥2 years post-HSCT
Correlation between insulin sensitivity and risk factors associated with metabolic syndrome
Timeframe: ≥2 years post-HSCT
Influence of time since transplant on insulin resistance
Timeframe: ≥2 years post-HSCT
Peak growth hormone secretion in patients with insulin resistance and in those without
Timeframe: ≥2 years post-HSCT
Growth hormone deficiency in patients with metabolic syndrome and in those without
Timeframe: ≥2 years post-HSCT
Association of interleukin-6, tumor necrosis factor-α, C-reactive protein, and leptin with insulin resistance and central obesity
Timeframe: ≥2 years post-HSCT
Correlation of adiponectin with insulin resistance and central obesity
Timeframe: ≥2 years post-HSCT
Differences in markers for endothelium dysfunction and early indicators of cardiovascular disease
Timeframe: ≥2 years post-HSCT
Difference in important health behaviors related to obesity and cardiovascular disease between patients with metabolic syndrome and those without
Timeframe: ≥2 years post-HSCT